Loading
Sarcoma surgeon who led the ISG-STS 1001 trial of histology-tailored neoadjuvant chemotherapy.
Alessandro Gronchi is Chair of the Sarcoma Service at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, a surgeon whose specialisms are sarcoma surgery, retroperitoneal sarcoma and neoadjuvant chemotherapy. He is known for chairing ISG-STS 1001, the randomised trial that compared histology-tailored neoadjuvant chemotherapy with standard chemotherapy in high-risk soft-tissue sarcoma, and STRASS, which tested preoperative radiotherapy. His Lancet Oncology paper on ISG-STS 1001 set out how tailoring chemotherapy to sarcoma histotype compares with a standard regimen. He continues to lead the sarcoma surgical programme at INT Milan, with his publications listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001) | Lancet Oncology | 2017 |
Shares ISG-STS 1001, Fondazione IRCCS Istituto Nazionale dei Tumori, Sarcomas (soft tissue, bone, GIST).
Shares ISG-STS 1001, A same-week expert second opinion for every rare cancer diagnosis, Sarcomas (soft tissue, bone, GIST).
Shares Fondazione IRCCS Istituto Nazionale dei Tumori, A same-week expert second opinion for every rare cancer diagnosis.
Shares Fondazione IRCCS Istituto Nazionale dei Tumori, Sarcomas (soft tissue, bone, GIST).
Shares A same-week expert second opinion for every rare cancer diagnosis, Sarcomas (soft tissue, bone, GIST).
Shares European Society of Surgical Oncology, Sarcomas (soft tissue, bone, GIST).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/